With its launch of chronic myeloid leukemia drug Iclusig, Ariad Pharmaceuticals just topped Wall Street estimates for the quarter and is showing significant promise despite what on the surface appear to be meager numbers.
In this video, health-care analyst David Williamson discusses its potential to continue to surprise investors and beat Wall Street going forward. Watch and find out if Ariad is a stock investors need on their radars.
What could be a slam-dunk for investors is a company working to eradicate the macro trend Warren Buffett called "the tapeworm that's eating at American competitiveness." Find out what Buffett was referring to in our free report: "What's Really Eating at America's Competitiveness." Just click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.